Ilana Schlam
@ilanaschlam.bsky.social
Breast medical oncologist @Dana-Farber | Harvard | Posts are my own and not medical advise
Pinned
Ilana Schlam
@ilanaschlam.bsky.social
· Nov 17
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
Reposted by Ilana Schlam
📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social
January 19, 2025 at 11:11 AM
📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social
Reposted by Ilana Schlam
Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
January 15, 2025 at 3:59 PM
Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
Reposted by Ilana Schlam
🔥Nature Medicine🆙
✅Evaluating generalizability of oncology trial results to real-world pts using machine learning-based trial emulations
🎯Decision support/estimation of RW treatment benefit
👥Drs. Xavier Orcutt, Ravi B. Parikh et al.
#LCSM @oncoalert.bsky.social #AI
www.nature.com/articles/s41...
✅Evaluating generalizability of oncology trial results to real-world pts using machine learning-based trial emulations
🎯Decision support/estimation of RW treatment benefit
👥Drs. Xavier Orcutt, Ravi B. Parikh et al.
#LCSM @oncoalert.bsky.social #AI
www.nature.com/articles/s41...
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations - Nature Medicine
Machine-learning-based and population-level electronic health record data–based emulation of landmark phase 3 randomized controlled trials (RCTs) in oncology across a range of cancer and risk types sh...
www.nature.com
January 4, 2025 at 2:14 PM
🔥Nature Medicine🆙
✅Evaluating generalizability of oncology trial results to real-world pts using machine learning-based trial emulations
🎯Decision support/estimation of RW treatment benefit
👥Drs. Xavier Orcutt, Ravi B. Parikh et al.
#LCSM @oncoalert.bsky.social #AI
www.nature.com/articles/s41...
✅Evaluating generalizability of oncology trial results to real-world pts using machine learning-based trial emulations
🎯Decision support/estimation of RW treatment benefit
👥Drs. Xavier Orcutt, Ravi B. Parikh et al.
#LCSM @oncoalert.bsky.social #AI
www.nature.com/articles/s41...
The BRIDGES study @JCO GO
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
December 20, 2024 at 9:12 PM
The BRIDGES study @JCO GO
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
Reposted by Ilana Schlam
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
December 11, 2024 at 9:42 PM
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
Reposted by Ilana Schlam
🩸🧬Exciting update!
LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology!
@oncoalert.bsky.social
@christianrolfo.bsky.social
@viveksubbiah.bsky.social
www.annalsofoncology.org/action/showP...
LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology!
@oncoalert.bsky.social
@christianrolfo.bsky.social
@viveksubbiah.bsky.social
www.annalsofoncology.org/action/showP...
December 17, 2024 at 2:29 PM
🩸🧬Exciting update!
LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology!
@oncoalert.bsky.social
@christianrolfo.bsky.social
@viveksubbiah.bsky.social
www.annalsofoncology.org/action/showP...
LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology!
@oncoalert.bsky.social
@christianrolfo.bsky.social
@viveksubbiah.bsky.social
www.annalsofoncology.org/action/showP...
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 8:08 PM
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Reposted by Ilana Schlam
Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 3:12 PM
Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
December 12, 2024 at 5:57 PM
PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social
December 12, 2024 at 1:50 PM
Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social
Stellar discussion by Dr Burstein
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
December 11, 2024 at 3:58 PM
Stellar discussion by Dr Burstein
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
Reposted by Ilana Schlam
#EMBER3
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 3:27 PM
#EMBER3
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Reposted by Ilana Schlam
Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?
December 11, 2024 at 2:13 PM
Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?
Reposted by Ilana Schlam
Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX
#MedSky #SABCS24
#MedSky #SABCS24
December 11, 2024 at 2:15 PM
Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.
Reposted by Ilana Schlam
We're kicking off the first day of our LIVE coverage of #SABCS24 with expert insights from @ilanaschlam.bsky.social of @danafarber.bsky.social, who will be taking over the @OncLive X and Bluesky🦋 accounts to cover this evening's sessions! Be sure to tune in! @sabcs.bsky.social #bcsm #oncology
December 10, 2024 at 5:11 PM
We're kicking off the first day of our LIVE coverage of #SABCS24 with expert insights from @ilanaschlam.bsky.social of @danafarber.bsky.social, who will be taking over the @OncLive X and Bluesky🦋 accounts to cover this evening's sessions! Be sure to tune in! @sabcs.bsky.social #bcsm #oncology
The ASCO virtual mentoring program (VMP) is now accepting applications; this is a great opportunity for trainees. This program was career-changing for me. Consider applying!
@stolaney1.bsky.social @dfcibreastonc.bsky.social
asco.smapply.org/prog/2025-26...
@stolaney1.bsky.social @dfcibreastonc.bsky.social
asco.smapply.org/prog/2025-26...
2025-26 ASCO Virtual Mentoring Program - Application Portal
asco.smapply.org
December 10, 2024 at 3:20 PM
The ASCO virtual mentoring program (VMP) is now accepting applications; this is a great opportunity for trainees. This program was career-changing for me. Consider applying!
@stolaney1.bsky.social @dfcibreastonc.bsky.social
asco.smapply.org/prog/2025-26...
@stolaney1.bsky.social @dfcibreastonc.bsky.social
asco.smapply.org/prog/2025-26...
Reposted by Ilana Schlam
I created a SABCS Breast Thought Leader Starter Pack for anyone new to @bsky.app and following @sabcs.bsky.social
Will try to add all thought leaders as I go!
go.bsky.app/MkqBYa7
Will try to add all thought leaders as I go!
go.bsky.app/MkqBYa7
December 9, 2024 at 5:26 PM
I created a SABCS Breast Thought Leader Starter Pack for anyone new to @bsky.app and following @sabcs.bsky.social
Will try to add all thought leaders as I go!
go.bsky.app/MkqBYa7
Will try to add all thought leaders as I go!
go.bsky.app/MkqBYa7
Reposted by Ilana Schlam
Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
December 9, 2024 at 6:05 PM
Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
Reposted by Ilana Schlam
Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases.
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social
December 6, 2024 at 7:32 PM
Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases.
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social
Reposted by Ilana Schlam
Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social
December 6, 2024 at 3:51 AM
Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social
Reposted by Ilana Schlam
Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
academic.oup.com
November 29, 2024 at 2:16 PM
Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight:
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze
November 27, 2024 at 1:11 AM
Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight:
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze
Reposted by Ilana Schlam
Regular abstracts from #SABCS24 are out!
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
sabcs.org
November 25, 2024 at 11:41 PM
Regular abstracts from #SABCS24 are out!
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
Reposted by Ilana Schlam
Strong showing by #OhioState #BreastMedOnc for 100 top oncoinfluencers @stoverlab.bsky.social @quirogad.bsky.social Dr Arya Roy. Honored to be included and looking forward to this list for 🦋 next year! oncodaily.com/positive/bre...
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024 - OncoDaily
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024 / 2-PREVENT Breast Cancer TCE, ABCD After Breast Cancer Diagnosis,
oncodaily.com
November 23, 2024 at 11:02 PM
Strong showing by #OhioState #BreastMedOnc for 100 top oncoinfluencers @stoverlab.bsky.social @quirogad.bsky.social Dr Arya Roy. Honored to be included and looking forward to this list for 🦋 next year! oncodaily.com/positive/bre...
Reposted by Ilana Schlam
Findings highlight ‘critical importance’ of infectious complications after CAR-T - read HemeOncToday interview with Kai Rejeski and me #medsky #CARTcells www.healio.com/news/hematol...
Findings highlight ‘critical importance’ of infectious complications after CAR-T
Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.Unique CAR-T-specific side effects — s...
www.healio.com
November 18, 2024 at 3:51 AM
Findings highlight ‘critical importance’ of infectious complications after CAR-T - read HemeOncToday interview with Kai Rejeski and me #medsky #CARTcells www.healio.com/news/hematol...